查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1379979

mRNA 平台市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按適應症、可用性、mRNA 類型、最終用戶、地區和競爭細分

mRNA Platform Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Indication, by Usability, by mRNA Type, by End User, by region, and Competition
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

預計全球 mRNA 平台市場在預測期內將出現令人印象深刻的成長。 mRNA（信使RNA）平台是生物技術和醫學領域的尖端技術，它利用合成RNA分子向細胞傳遞遺傳訊息和指令，使它們能夠產生特定的蛋白質。這項技術獲得了極大的關注和成功，特別是在疫苗開發和各種疾病的治療方面。 mRNA 是一種遺傳物質，通常將 DNA（遺傳密碼）的指令傳遞給細胞的蛋白質製造機器（核醣體）。它充當基因指令的臨時副本。在 mRNA 平台中，合成或修飾的 mRNA 分子被設計為攜帶用於生產特定蛋白質的特定遺傳指令。科學家可以設計和合成具有精確遺傳訊息的mRNA序列。這些資訊可以客製化用於各種目的，例如生產治療性蛋白質或指示免疫系統產生免疫反應。在疫苗開發中，mRNA 平台用於創建 mRNA 疫苗。這些疫苗含有編碼部分目標病原體的 mRNA 分子，例如病毒蛋白或獨特抗原。

主要市場促進因素

技術進步

脂質奈米顆粒 (LNP) 遞送系統對於有效地將 mRNA 遞送至細胞至關重要。 LNP 設計和配方的進步提高了 mRNA 疫苗和療法的穩定性、傳遞和功效。這些進步對 COVID-19 mRNA 疫苗的成功發揮了關鍵作用。研究人員開發了經過修飾的 mRNA 序列，其穩定性增強，免疫原性降低。這延長了 mRNA 疫苗的保存期限，使其更適合分發和儲存。密碼子最佳化涉及修改遺傳密碼以改善蛋白質表現。研究人員一直在微調密碼子的使用以增強蛋白質的產生，這對於治療應用尤其重要。 CRISPR-Cas9 等合成生物學技術的進步促進了 mRNA 序列的精確編輯和操作。這項技術為基於 mRNA 的遺傳性疾病療法開闢了新的可能性。可擴展且具有成本效益的製造流程已被開發出來，以滿足對基於 mRNA 的疫苗和療法的高需求。這些製造業的改進使得在突發公共衛生事件期間能夠快速生產。研究人員在提高 mRNA 疫苗在不同溫度範圍內的穩定性、減少超低溫儲存和分發的需求方面取得了進展。新一代定序 (NGS) 使研究人員能夠快速、準確地分析 mRNA 序列，從而有助於設計針對特定標靶的基於 mRNA 的療法。

將帽子類似物添加到 mRNA 序列的開頭以模擬天然 mRNA。這提高了合成 mRNA 的翻譯效率並增加了其與內源性 mRNA 的相似性。用於 mRNA 生產的無細胞系統已經開發出來，可以更有效、更大規模地合成 mRNA 分子，用於研究和治療目的。 mRNA 技術的進步促進了個人化醫療方法的發展，其中治療方法是根據個人的基因圖譜量身定做的。佐劑是一種添加到疫苗中以增強免疫反應的物質。研究重點是開發專門為基於 mRNA 的疫苗設計的新型佐劑。細胞內遞送方法的創新，例如電穿孔和微針貼片，提高了 mRNA 進入目標細胞的效率。對 mRNA 配方和穩定性的廣泛研究提高了在各種條件下儲存和運輸 mRNA 疫苗和療法的能力。這一因素將有助於全球 mRNA 平台市場的發展。

新興應用

最有前景的新興應用之一是癌症免疫療法。研究人員正在開發基於 mRNA 的癌症疫苗和療法，以刺激患者的免疫系統瞄準並摧毀癌細胞。這種方法為各種類型的癌症提供了個人化且可能更有效的治療方法。雖然mRNA 疫苗已經證明了其針對COVID-19 等傳染病的有效性，但正在進行的研究旨在開發針對其他傳染病的基於mRNA 的疫苗，例如流感、愛滋病毒、寨卡病毒和呼吸道合胞病毒(RSV)。 mRNA 技術的適應性使其非常適合應對新出現的病原體。 mRNA 技術正在探索用於治療由特定突變引起的罕見遺傳性疾病。透過提供修飾的 mRNA 來糾正遺傳缺陷，研究人員旨在為患有囊性纖維化和某些遺傳性代謝紊亂等疾病的患者提供有針對性的個人化治療。 mRNA技術透過引導幹細胞分化為特定細胞類型以進行組織修復和替換，在再生醫學中具有潛在應用。這對於治療退化性疾病和損傷特別有價值。 mRNA 可用於提供 CRISPR-Cas9 等基因編輯工具來針對和修改特定基因。這項技術有望治療遺傳疾病和糾正基因突變。研究人員正在探索 mRNA 來取代或補充遺傳性或後天性蛋白質缺陷患者的缺陷蛋白質。這種方法可用於治療血友病和某些酵素缺乏症等疾病。

mRNA 技術正在研究用於開發自體免疫疾病的療法。透過調節免疫反應，基於 mRNA 的治療可能有助於調節和控制自體免疫疾病。 mRNA 疫苗可以客製化，以提供針對過敏的過敏原特異性免疫療法。這種方法提供了更精確、更有效的過敏治療的潛力。根據個別基因圖譜客製化基於 mRNA 的療法的能力是個人化醫療的重要驅動力。根據患者獨特的基因組成客製化治療可以改善治療結果。除了醫療保健之外，mRNA 技術還應用於生物技術，包括重組蛋白和酵素的生產。它還具有在農業和工業生物技術等其他領域的應用潛力。這項因素將加快全球 mRNA 平台市場的需求。

流行病應對和疫苗的成長

mRNA 技術促進了 COVID-19 疫苗的快速開發。在非常短的時間內，Pfizer-BioNTech 和 Moderna 等公司開發、測試了基於 mRNA 的 COVID-19 疫苗，並獲得了緊急使用授權。這種發展速度對於控制疫情至關重要。 mRNA 疫苗已表現出針對 COVID-19 的高水平功效，有助於其快速採用和廣泛使用。這些疫苗在預防嚴重疾病和傳播方面的有效性一直是需求的強勁推動力。 mRNA技術非常適合適應新的病毒變種。 mRNA 的靈活性允許快速修改候選疫苗，以應對新出現的病毒變種，從而解決面對病毒突變時疫苗有效性的擔憂。 mRNA 疫苗的可擴展性和快速生產能力支持了全球疫苗接種工作。各國政府、國際組織和醫療保健系統都在尋求 mRNA 疫苗來保護其人口，推動了增加產量的需求。

這次大流行凸顯了為新出現的傳染病做好準備的重要性。世界各國政府和組織已經認知到 mRNA 技術在快速應對未來流行病的潛力，並投資建設基礎設施和能力。基於 mRNA 的 COVID-19 疫苗的成功吸引了公共和私營部門的大量投資和資金。這項資金支持加速了研發工作並擴大了 mRNA 平台的應用。包括美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 在內的監管機構與 mRNA 技術開發商密切合作，以加速突發公共衛生事件期間的法規核准流程。 mRNA COVID-19 疫苗的有效性和安全性增強了公眾對該技術的信心。因此，人們對基於 mRNA 的疫苗和療法的接受度有所提高。 mRNA疫苗的成功刺激了該領域的進一步研究和開發。研究人員和公司正在探索 mRNA 技術在廣泛應用中的潛力，包括其他傳染病的疫苗和療法。全球應對這場流行病需要各國、製藥公司和研究機構之間的合作。此次合作加速了 mRNA 技術知識和專業知識的分享。這一因素將加速全球 mRNA 平台市場的需求。

主要市場挑戰

疫苗猶豫和錯誤訊息

疫苗猶豫是指不願意或拒絕接種疫苗，可能會減慢 mRNA 疫苗的採用。這可能會阻礙群體免疫和控制傳染病傳播的努力。錯誤訊息通常透過社群媒體和其他管道傳播，可能導致人們對 mRNA 疫苗產生誤解和錯誤信念。這可能包括對疫苗安全性、有效性和長期影響的擔憂。錯誤訊息可能會削弱公眾對疫苗的信心並阻止個人接種疫苗。由於猶豫和錯誤訊息而導致的疫苗覆蓋率降低可能會導致可預防疾病的持續爆發，包括潛在致命的傳染病，如 COVID-19。這些疫情可能會對醫療保健系統造成壓力，導致發病率和死亡率增加，並產生經濟和社會後果。對疫苗的高度猶豫可能會阻礙群體免疫的努力，而群體免疫對於保護因醫療原因無法接種疫苗的弱勢群體至關重要。群體免疫對於控制傳染病在社區內的傳播至關重要。錯誤訊息和猶豫不決可能會擾亂疫苗接種活動，並導致疫苗接種率降低，特別是在流行病等突發公共衛生事件期間。普遍的疫苗猶豫和疫苗錯誤訊息的傳播可能會削弱公眾對公共衛生機構、醫療保健提供者和政府建議的信任。這種信任的侵蝕可能會延伸到其他公共衛生措施，使實施有效的疾病控制策略更具挑戰性。

變體和適應性

許多傳染性病原體，特別是病毒，可能會發生基因突變，導致新變種或病毒株的出現。這些變體可能具有不同的特性，包括增加的傳播性和免疫力。變異可能導致更嚴重的疾病或降低疫苗有效性，對公共衛生構成威脅。疫苗（包括 mRNA 疫苗）的有效性可能因不同變異而異。有些變體可能部分逃避現有疫苗誘發的免疫反應。這挑戰了疫苗針對不斷進化的病原體提供廣泛而持久的保護的能力。為了維持疫苗的有效性，研究人員和製造商需要快速調整 mRNA 疫苗以應對新出現的變異。這可能涉及修改 mRNA 序列以編碼新變異體的抗原。在大流行和爆發期間，快速適應對於確保疫苗保持有效至關重要。監管機構可能需要為變異疫苗提供簡化的核准流程，以加快其在公共衛生緊急情況下的可用性。開發變體特異性疫苗並獲得監管部門的批准可能會佔用大量資源且耗時。調整 mRNA 疫苗以應對新變種可能需要調整製造流程。擴大生產以滿足全球對更新疫苗的需求可能具有挑戰性。

主要市場趨勢

個人化醫療

基因組學和基因測試的進步使得快速且經濟地分析個體遺傳資訊變得越來越可行。這種基因分析使醫療保健提供者能夠識別可能影響疾病易感性和治療反應的基因變異。 mRNA 技術能夠開發可根據患者基因圖譜量身定做的標靶療法。透過設計 mRNA 序列來解決特定的遺傳變異或疾病標記，研究人員可以創建個人化的治療方法。在癌症方面，個人化醫療是一個值得注意的應用。研究人員正在探索基於 mRNA 的癌症疫苗和針對個人化腫瘤抗原的療法。這些療法旨在利用患者的免疫系統來專門瞄準並摧毀癌細胞。個人化 mRNA 療法正在開發中，以解決由特定突變引起的罕見遺傳疾病。透過客製化 mRNA 序列來糾正或補償這些突變，研究人員正在努力提供個人化治療。 mRNA 疫苗可以客製化，以提供針對過敏的過敏原特異性免疫療法。這種方法有可能針對每位患者的過敏原進行更精確、更有效的過敏治療。 mRNA 技術可以透過分析基因表現的變化來監測患者對治療的反應。這些資訊可用於調整和個人化治療計劃。將藥物基因組資料與基於 mRNA 的療法相結合，有助於確定最適合個別患者的藥物和劑量，減少不良反應並最佳化治療結果。

細分市場洞察

適應症見解

2022 年，全球 mRNA 平台市場最大佔有率由自體免疫疾病領域佔據，預計未來幾年將繼續擴大。由於自體免疫疾病的複雜性和人們對自體免疫疾病的本質了解甚少，因此自體免疫疾病是一項重大的醫學挑戰。許多自體免疫疾病的治療選擇有限，而 mRNA 技術有望開發創新療法，以滿足該領域未滿足的醫療需求。 mRNA技術可用於調節免疫系統，使其成為治療自體免疫疾病的一種有吸引力的方法。透過設計針對特定免疫反應的 mRNA 序列，研究人員可以潛在地抑製或調節免疫系統在自體免疫條件下的有害活動。自體免疫疾病患者的表現和治療反應通常各不相同。基於 mRNA 的療法可以針對特定的自身免疫途徑或抗原進行客製化，從而實現個人化的治療方法。

可用性見解

2022 年，治療性疫苗領域佔據全球 mRNA 平台市場最大佔有率，預計未來幾年將繼續擴大。 COVID-19 大流行對 mRNA 平台市場產生了重大影響。 mRNA 技術的出現是一種高效、快速的反應，可用於開發針對 SARS-CoV-2 病毒的疫苗。基於 mRNA 的 COVID-19 疫苗（例如輝瑞 BioNTech 和 Moderna 開發的疫苗）的成功引起了對該領域的巨大興趣和投資。 mRNA技術已在開發針對傳染病以外的各種疾病的治療性疫苗方面展示了其多功能性。這包括癌症疫苗（基於 mRNA 的療法旨在刺激免疫系統瞄準並摧毀癌細胞），以及針對流感、寨卡病毒和愛滋病毒等其他疾病的疫苗。 mRNA疫苗和治療性疫苗的開發速度比傳統疫苗平台更快。這種速度對於應對新出現的傳染病和快速進化的病原體尤其有價值。

mRNA 型見解

2022 年，全球 mRNA 平台市場最大佔有率由自放大 mRNA 細分市場佔據，預計未來幾年將持續擴大。與傳統 mRNA 相比，自擴增 mRNA (saRNA) 技術旨在產生更高水平的蛋白質表現。這種增強的蛋白質生產能力可以使 saRNA 對於疫苗開發和針對需要強大免疫反應的疾病的療法特別有吸引力。自我擴增 mRNA 可以被設計為攜帶多種抗原或治療蛋白質的遺傳訊息。這種多功能性使其成為開發各種疾病（包括傳染病和癌症）的疫苗和療法的寶貴工具。用於傳遞自放大 mRNA 的先進脂質奈米粒子 (LNP) 的開發提高了基於 saRNA 的疫苗和療法的穩定性和傳遞效率，進一步擴大了其市場佔有率。

最終使用者見解

2022 年，全球 mRNA 平台市場最大佔有率由製藥公司部門在預測期內佔據，預計未來幾年將繼續擴大。製藥公司在藥物發現和開發領域進行廣泛的研究和開發 (R&D) 有著悠久的歷史。他們擁有推進基於 mRNA 的療法和疫苗所需的科學專業知識、基礎設施和財政資源。 mRNA 技術在開發針對多種疾病的疫苗和療法方面顯示出巨大的前景，包括傳染病、癌症和罕見的遺傳性疾病。製藥公司擁有將這些產品從研究階段帶到臨床試驗並最終商業化的經驗和能力。進行臨床試驗是藥物開發的關鍵部分。製藥公司有能力進行大規模臨床試驗，這對於獲得監管部門的批准並證明基於 mRNA 的產品的安全性和有效性是必要的。

區域洞察

2022年，北美地區將主導全球mRNA平台市場。北美是一些全球最大、最有影響力的生物技術和製藥公司的所在地，其中許多公司在mRNA技術上投入了大量資金。輝瑞 (Pfizer)、Moderna 和 BioNTech 等公司在基於 mRNA 的 COVID-19 疫苗的開發和商業化中發揮了關鍵作用，其總部或在北美擁有重要業務。該地區擁有完善而強大的生物醫學研究和開發生態系統。它擁有世界一流的大學、研究機構和致力於推進 mRNA 技術的高技能勞動力。北美為 mRNA 研發吸引了大量投資和資金。公共和私人資助機構、創投家和政府措施支持了基於 mRNA 的療法和疫苗的發展。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球 mRNA 平台市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依適應症（自體免疫疾病、癌症、傳染病、罕見疾病、呼吸系統疾病）
    • 依可用性分類（預防性疫苗、治療性藥物、治療性疫苗）
    • 依 mRNA 類型（核苷修飾 mRNA 、自擴增 mRNA 、未修飾 mRNA ）
    • 按最終用戶（醫院和診所、製藥公司、研究組織）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：亞太地區 mRNA 平台市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按指示
    • 按可用性
    • 依 mRNA 類型
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國mRNA平台
    • 印度 mRNA 平台
    • 澳洲 mRNA 平台
    • 日本mRNA平台
    • 韓國 mRNA 平台

第 7 章：歐洲 mRNA 平台市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按指示
    • 按可用性
    • 依 mRNA 類型
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 8 章：北美 mRNA 平台市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按指示
    • 按可用性
    • 依 mRNA 類型
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 9 章：南美洲 mRNA 平台市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按指示
    • 按可用性
    • 依 mRNA 類型
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲 mRNA 平台市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按指示
    • 按可用性
    • 依 mRNA 類型
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非 mRNA 平台
    • 沙烏地阿拉伯 mRNA 平台
    • 阿拉伯聯合大公國 mRNA 平台

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：全球 mRNA 平台市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第 15 章：大環境分析

第16章：競爭格局

  • 安進公司阿斯特捷利康公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 阿蘇拉根公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 康泰倫特製藥解決方案
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Arcturus 治療公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 生技公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • CRISPR 治療公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • AKESOgen 公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 基克克有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 口音治療公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Accanis Biotech F&E GmbH & Co KG
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis

第 17 章：策略建議

第 18 章：關於我們與免責聲明

簡介目錄
Product Code: 17266

Global mRNA Platform Market is anticipated to witness an impressive growth in the forecast period. The mRNA (messenger RNA) platform is a cutting-edge technology in biotechnology and medicine that uses synthetic RNA molecules to convey genetic information and instructions to cells, allowing them to produce specific proteins. This technology has gained significant attention and success, particularly in vaccine development and the treatment of various diseases. mRNA is a type of genetic material that normally carries instructions from DNA (the genetic code) to the cell's protein-making machinery (ribosomes). It serves as a temporary copy of a gene's instructions. In the mRNA platform, synthetic or modified mRNA molecules are designed to carry specific genetic instructions for producing a particular protein. Scientists can design and synthesize mRNA sequences with precise genetic information. This information can be customized for various purposes, such as producing therapeutic proteins or instructing the immune system to generate an immune response. In vaccine development, the mRNA platform is used to create mRNA vaccines. These vaccines contain mRNA molecules that encode a portion of the target pathogen, such as a viral protein or a unique antigen.

Beyond vaccines, the mRNA platform is used for therapeutic purposes. Researchers are exploring mRNA-based therapies for a wide range of conditions, including cancer, genetic disorders, autoimmune diseases, and allergies. In cancer immunotherapy, for example, mRNA is designed to instruct immune cells to target and attack cancer cells, harnessing the body's immune system to fight the disease. The COVID-19 pandemic accelerated the adoption of mRNA technology for vaccine development. The success of mRNA vaccines for COVID-19 generated enormous interest and investment in this technology, highlighting its potential in responding to emerging infectious diseases. mRNA technology's versatility allows for the development of vaccines and therapies for a wide range of diseases, including infectious diseases, cancer, genetic disorders, and autoimmune conditions. This adaptability makes it an attractive platform for addressing various medical challenges.

Key Market Drivers

Technological Advancements

Lipid Nanoparticle (LNP) Delivery Systems are crucial for delivering mRNA to cells efficiently. Advances in LNP design and formulation have improved the stability, delivery, and efficacy of mRNA vaccines and therapies. These advancements have played a pivotal role in the success of COVID-19 mRNA vaccines. Researchers have developed modified mRNA sequences with enhanced stability and reduced immunogenicity. This has extended the shelf life of mRNA vaccines and made them more suitable for distribution and storage. Codon optimization involves modifying the genetic code to improve protein expression. Researchers have been fine-tuning codon usage to enhance protein production, which is particularly important for therapeutic applications. Advances in synthetic biology techniques, such as CRISPR-Cas9, have facilitated the precise editing and manipulation of mRNA sequences. This technology has opened new possibilities for mRNA-based therapies targeting genetic diseases. Scalable and cost-effective manufacturing processes have been developed to meet the high demand for mRNA-based vaccines and therapies. These improvements in manufacturing have enabled rapid production during public health emergencies. Researchers have made progress in increasing the stability of mRNA vaccines at various temperature ranges, reducing the need for ultra-low-temperature storage and distribution. Next-Generation Sequencing (NGS) has enabled researchers to analyze mRNA sequences rapidly and accurately, facilitating the design of mRNA-based therapies tailored to specific targets.

Cap analogues are added to the beginning of mRNA sequences to mimic natural mRNA. This improves the translational efficiency of synthetic mRNA and increases its similarity to endogenous mRNA. Cell-free systems for mRNA production have been developed, allowing for more efficient and scalable synthesis of mRNA molecules for research and therapeutic purposes. Advancements in mRNA technology have enabled the development of personalized medicine approaches, where therapies are tailored to an individual's genetic profile. Adjuvants are substances added to vaccines to enhance the immune response. Research has focused on developing novel adjuvants specifically designed for mRNA-based vaccines. Innovations in intracellular delivery methods, such as electroporation and microneedle patches, have improved the efficient uptake of mRNA into target cells. Extensive research into mRNA formulation and stability has improved the ability to store and transport mRNA vaccines and therapies under various conditions. This factor will help in the development of the Global mRNA Platform Market.

Emerging Applications

One of the most promising emerging applications is cancer immunotherapy. Researchers are developing mRNA-based cancer vaccines and therapies that stimulate the patient's immune system to target and destroy cancer cells. This approach offers a personalized and potentially more effective treatment for various types of cancer. While mRNA vaccines have already demonstrated their effectiveness against infectious diseases like COVID-19, ongoing research aims to develop mRNA-based vaccines for other infectious diseases, such as influenza, HIV, Zika virus, and respiratory syncytial virus (RSV). The adaptability of mRNA technology makes it well-suited for responding to emerging pathogens. mRNA technology is being explored for the treatment of rare genetic disorders caused by specific mutations. By delivering modified mRNA to correct genetic defects, researchers aim to provide targeted and personalized therapies for patients with conditions like cystic fibrosis and certain inherited metabolic disorders. mRNA technology has potential applications in regenerative medicine by guiding the differentiation of stem cells into specific cell types for tissue repair and replacement. This could be particularly valuable for treating degenerative diseases and injuries. mRNA can be used to deliver gene-editing tools like CRISPR-Cas9 to target and modify specific genes. This technology holds promise for treating genetic diseases and correcting genetic mutations. Researchers are exploring mRNA to replace or supplement deficient proteins in patients with genetic or acquired protein deficiencies. This approach can be used to treat conditions like hemophilia and certain enzyme deficiencies.

mRNA technology is being investigated for the development of therapies for autoimmune diseases. By modulating the immune response, mRNA-based treatments may help regulate and control autoimmune conditions. mRNA vaccines can be customized to deliver allergen-specific immunotherapy for allergies. This approach offers the potential for more precise and effective allergy treatments. The ability to customize mRNA-based therapies based on an individual's genetic profile is a significant driver in personalized medicine. Tailoring treatments to a patient's unique genetic makeup can improve treatment outcomes. Beyond healthcare, mRNA technology has applications in biotechnology, including the production of recombinant proteins and enzymes. It also holds potential for use in other fields, such as agriculture and industrial biotechnology. This factor will pace up the demand of the Global mRNA Platform Market.

Growth in Pandemic Response and Vaccines

mRNA technology allowed for the rapid development of COVID-19 vaccines. Within a remarkably short timeframe, companies like Pfizer-BioNTech and Moderna developed, tested, and received emergency use authorization for mRNA-based COVID-19 vaccines. This speed of development was crucial in controlling the pandemic. mRNA vaccines have demonstrated high levels of efficacy against COVID-19, contributing to their rapid adoption and widespread use. The effectiveness of these vaccines in preventing severe illness and transmission has been a strong driver of demand. mRNA technology is well-suited to adapt to new virus variants. The flexibility of mRNA allows for the quick modification of vaccine candidates to address emerging variants of the virus, addressing concerns about vaccine effectiveness in the face of viral mutations. The scalability and rapid production capabilities of mRNA vaccines have supported global vaccination efforts. Governments, international organizations, and healthcare systems have sought to secure mRNA vaccines to protect their populations, driving demand for increased production.

The pandemic highlighted the importance of being prepared for emerging infectious diseases. Governments and organizations worldwide have recognized the potential of mRNA technology to respond quickly to future pandemics and have invested in building infrastructure and capabilities. The success of mRNA-based COVID-19 vaccines attracted substantial investment and funding from both the public and private sectors. This financial support has accelerated research and development efforts and expanded the mRNA platform's applications. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), collaborated closely with mRNA technology developers to expedite the regulatory approval process during public health emergencies. The effectiveness and safety of mRNA COVID-19 vaccines have contributed to public confidence in this technology. As a result, there has been increased acceptance of mRNA-based vaccines and therapies. The success of mRNA vaccines has spurred further research and development in the field. Researchers and companies are exploring the potential of mRNA technology for a wide range of applications, including vaccines and therapies for other infectious diseases. The global response to the pandemic has involved collaboration between countries, pharmaceutical companies, and research institutions. This collaboration has accelerated the sharing of knowledge and expertise in mRNA technology. This factor will accelerate the demand of the Global mRNA Platform Market.

Key Market Challenges

Vaccine Hesitancy and Misinformation

Vaccine hesitancy, which refers to the reluctance or refusal to get vaccinated, can slow down the adoption of mRNA vaccines. This can impede efforts to achieve herd immunity and control the spread of infectious diseases. Misinformation, often spread through social media and other channels, can lead to misconceptions and false beliefs about mRNA vaccines. This can include concerns about vaccine safety, efficacy, and long-term effects. Misinformation can undermine public confidence in vaccines and deter individuals from getting vaccinated. Lower vaccine coverage due to hesitancy and misinformation can lead to ongoing outbreaks of preventable diseases, including potentially deadly infectious diseases like COVID-19. These outbreaks can strain healthcare systems, result in increased morbidity and mortality, and have economic and societal consequences. High levels of vaccine hesitancy can hinder efforts to achieve herd immunity, which is essential for protecting vulnerable populations who cannot receive vaccines due to medical reasons. Herd immunity is crucial for controlling the spread of contagious diseases within communities. Misinformation and hesitancy can disrupt vaccination campaigns and lead to lower vaccine uptake rates, particularly during public health emergencies like pandemics. Widespread vaccine hesitancy and the propagation of vaccine misinformation can erode public trust in public health institutions, healthcare providers, and government recommendations. This erosion of trust can extend to other public health measures, making it more challenging to implement effective disease control strategies.

Variants and Adaptability

Many infectious pathogens, particularly viruses, can undergo genetic mutations that result in the emergence of new variants or strains. These variants can have different properties, including increased transmissibility and resistance to immunity. Variants can pose a threat to public health by potentially leading to more severe disease or reduced vaccine effectiveness. The effectiveness of vaccines, including mRNA vaccines, can vary against different variants. Some variants may partially evade the immune response induced by existing vaccines. This challenges the ability of vaccines to provide broad and long-lasting protection against evolving pathogens. To maintain vaccine effectiveness, researchers and manufacturers need to adapt mRNA vaccines quickly to address emerging variants. This may involve modifying the mRNA sequence to encode the antigen(s) of the new variant. Rapid adaptation is critical during pandemics and outbreaks to ensure that vaccines remain effective. Regulatory agencies may need to provide streamlined approval processes for variant-adapted vaccines to expedite their availability during public health emergencies. Developing and gaining regulatory approval for variant-specific vaccines can be resource-intensive and time-consuming. Adapting mRNA vaccines to address new variants may require adjustments in the manufacturing process. Scaling up production to meet global demand for updated vaccines can be challenging.

Key Market Trends

Personalized Medicine

Advances in genomics and genetic testing have made it increasingly feasible to analyze an individual's genetic information quickly and affordably. This genetic profiling allows healthcare providers to identify genetic variations that may impact disease susceptibility and treatment responses. mRNA technology enables the development of targeted therapies that can be customized based on a patient's genetic profile. By designing mRNA sequences to address specific genetic variations or disease markers, researchers can create personalized treatments. In the context of cancer, personalized medicine was a notable application. Researchers were exploring mRNA-based cancer vaccines and therapies that target individualized tumor antigens. These therapies aim to harness the patient's immune system to target and destroy cancer cells specifically. Personalized mRNA therapies were being developed to address rare genetic diseases caused by specific mutations. By tailoring mRNA sequences to correct or compensate for these mutations, researchers were working to provide individualized treatments. mRNA vaccines can be customized to deliver allergen-specific immunotherapy for allergies. This approach offers the potential for more precise and effective allergy treatments tailored to each patient's allergens. mRNA technology allows for the monitoring of a patient's response to treatment by analyzing changes in gene expression. This information can be used to adjust and personalize treatment plans. Integrating pharmacogenomic data with mRNA-based therapies can help determine the most suitable medications and dosages for individual patients, reducing adverse effects and optimizing treatment outcomes.

Segmental Insights

Indication Insights

In 2022, the Global mRNA Platform Market largest share was held by Autoimmune Diseases segment and is predicted to continue expanding over the coming years. Autoimmune diseases represent a significant medical challenge due to their complex and often poorly understood nature. Many autoimmune diseases have limited treatment options, and mRNA technology holds promise for developing innovative therapies to address unmet medical needs in this segment. mRNA technology can be used to modulate the immune system, making it an attractive approach for treating autoimmune diseases. By designing mRNA sequences to target specific immune responses, researchers can potentially suppress or regulate the immune system's harmful activities in autoimmune conditions. Autoimmune diseases often have variable manifestations and responses to treatment among patients. mRNA-based therapies can be customized to target specific autoimmune pathways or antigens, allowing for a personalized approach to treatment.

Usability Insights

In 2022, the Global mRNA Platform Market largest share was held by Therapeutic Vaccines segment and is predicted to continue expanding over the coming years. The COVID-19 pandemic had a significant impact on the mRNA platform market. mRNA technology emerged as a highly effective and rapid response to develop vaccines against the SARS-CoV-2 virus. The success of mRNA-based COVID-19 vaccines, such as those developed by Pfizer-BioNTech and Moderna, generated immense interest and investment in this segment. mRNA technology has demonstrated its versatility in the development of therapeutic vaccines for various diseases beyond infectious diseases. This includes cancer vaccines, where mRNA-based therapies aim to stimulate the immune system to target and destroy cancer cells, as well as vaccines for other diseases like influenza, Zika, and HIV. mRNA vaccines and therapeutic vaccines can be developed more rapidly than traditional vaccine platforms. This speed is especially valuable in responding to emerging infectious diseases and rapidly evolving pathogens.

mRNA Type Insights

In 2022, the Global mRNA Platform Market largest share was held by Self-Amplifying mRNA segment and is predicted to continue expanding over the coming years. Self-amplifying mRNA (saRNA) technology is designed to produce higher levels of protein expression compared to conventional mRNA. This enhanced protein production capability can make saRNA particularly attractive for vaccine development and therapies targeting diseases that require a robust immune response. Self-amplifying mRNA can be engineered to carry genetic information for a wide range of antigens or therapeutic proteins. This versatility makes it a valuable tool for developing vaccines and therapies against various diseases, including infectious diseases and cancer. The development of advanced lipid nanoparticles (LNPs) for the delivery of self-amplifying mRNA has improved the stability and delivery efficiency of saRNA-based vaccines and therapies, further contributing to their market share.

End-User Insights

In 2022, the Global mRNA Platform Market largest share was held by Pharmaceutical Companies segment in the forecast period and is predicted to continue expanding over the coming years. Pharmaceutical companies have a long history of conducting extensive research and development (R&D) in the field of drug discovery and development. They possess the scientific expertise, infrastructure, and financial resources required to advance mRNA-based therapies and vaccines. mRNA technology has shown immense promise for developing vaccines and therapeutics for a wide range of diseases, including infectious diseases, cancer, and rare genetic disorders. Pharmaceutical companies have the experience and capabilities to bring these products from the research stage to clinical trials and ultimately to commercialization. Running clinical trials is a critical part of drug development. Pharmaceutical companies have the capacity to conduct large-scale clinical trials, which are necessary for gaining regulatory approvals and demonstrating the safety and efficacy of mRNA-based products.

Regional Insights

The North America region dominates the Global mRNA Platform Market in 2022. North America is home to some of the world's largest and most influential biotechnology and pharmaceutical companies, many of which have invested heavily in mRNA technology. Companies like Pfizer, Moderna, and BioNTech, which played pivotal roles in the development and commercialization of mRNA-based COVID-19 vaccines, are headquartered, or have a significant presence in North America. The region has a well-established and robust ecosystem for biomedical research and development. It boasts world-class universities, research institutions, and a highly skilled workforce dedicated to advancing mRNA technology. North America has attracted substantial investment and funding for mRNA research and development. Public and private funding agencies, venture capitalists, and government initiatives have supported the growth of mRNA-based therapies and vaccines.

Key Market Players

  • AstraZeneca PLC
  • Asuragen, Inc.
  • Catalent Pharma Solutions
  • Arcturus Therapeutics, Inc.
  • BioNTech AG
  • CRISPR Therapeutics Inc.
  • AKESOgen, Inc.
  • baseclick GmbH
  • Accent Therapeutics Inc.
  • Accanis Biotech F&E GmbH & Co KG

Report Scope:

In this report, the Global mRNA Platform Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

mRNA Platform Market, By Indication:

  • Autoimmune Diseases
  • Cancer
  • Personalized Treatment
  • Single Cancer Focussed
  • Infectious Diseases
  • Rare Diseases
  • Respiratory Diseases

mRNA Platform Market, By Usability:

  • Prophylactic Vaccines
  • Therapeutic Drugs
  • Therapeutic Vaccines

mRNA Platform Market, By mRNA Type:

  • Nucleoside-Modified mRNA
  • Self-Amplifying mRNA
  • Unmodified mRNA

mRNA Platform Market, By End-User:

  • Hospitals & Clinics
  • Pharmaceutical Companies
  • Research Organization

Global mRNA Platform Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global mRNA Platform Market.

Available Customizations:

  • Global mRNA Platform Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global mRNA Platform Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Autoimmune Diseases, Cancer, Infectious Diseases, Rare Diseases, Respiratory Diseases)
    • 5.2.2. By Usability (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines)
    • 5.2.3. By mRNA Type (Nucleoside-Modified mRNA , Self-Amplifying mRNA , Unmodified mRNA )
    • 5.2.4. By End User (Hospitals & Clinics, Pharmaceutical Companies, Research Organization)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map

6. Asia Pacific mRNA Platform Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Usability
    • 6.2.3. By mRNA Type
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China mRNA Platform Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Usability
        • 6.3.1.2.3. By mRNA Type
        • 6.3.1.2.4. By End User
    • 6.3.2. India mRNA Platform Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Usability
        • 6.3.2.2.3. By mRNA Type
        • 6.3.2.2.4. By End User
    • 6.3.3. Australia mRNA Platform Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Usability
        • 6.3.3.2.3. By mRNA Type
        • 6.3.3.2.4. By End User
    • 6.3.4. Japan mRNA Platform Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Indication
        • 6.3.4.2.2. By Usability
        • 6.3.4.2.3. By mRNA Type
        • 6.3.4.2.4. By End User
    • 6.3.5. South Korea mRNA Platform Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Indication
        • 6.3.5.2.2. By Usability
        • 6.3.5.2.3. By mRNA Type
        • 6.3.5.2.4. By End User

7. Europe mRNA Platform Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Usability
    • 7.2.3. By mRNA Type
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France mRNA Platform Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Usability
        • 7.3.1.2.3. By mRNA Type
        • 7.3.1.2.4. By End User
    • 7.3.2. Germany mRNA Platform Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Usability
        • 7.3.2.2.3. By mRNA Type
        • 7.3.2.2.4. By End User
    • 7.3.3. Spain mRNA Platform Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Usability
        • 7.3.3.2.3. By mRNA Type
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy mRNA Platform Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Usability
        • 7.3.4.2.3. By mRNA Type
        • 7.3.4.2.4. By End User
    • 7.3.5. United Kingdom mRNA Platform Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Usability
        • 7.3.5.2.3. By mRNA Type
        • 7.3.5.2.4. By End User

8. North America mRNA Platform Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Usability
    • 8.2.3. By mRNA Type
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States mRNA Platform Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Usability
        • 8.3.1.2.3. By mRNA Type
        • 8.3.1.2.4. By End User
    • 8.3.2. Mexico mRNA Platform Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Usability
        • 8.3.2.2.3. By mRNA Type
        • 8.3.2.2.4. By End User
    • 8.3.3. Canada mRNA Platform Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Usability
        • 8.3.3.2.3. By mRNA Type
        • 8.3.3.2.4. By End User

9. South America mRNA Platform Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Usability
    • 9.2.3. By mRNA Type
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil mRNA Platform Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Usability
        • 9.3.1.2.3. By mRNA Type
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina mRNA Platform Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Usability
        • 9.3.2.2.3. By mRNA Type
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia mRNA Platform Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Usability
        • 9.3.3.2.3. By mRNA Type
        • 9.3.3.2.4. By End User

10. Middle East and Africa mRNA Platform Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Usability
    • 10.2.3. By mRNA Type
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa mRNA Platform Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Usability
        • 10.3.1.2.3. By mRNA Type
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia mRNA Platform Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Usability
        • 10.3.2.2.3. By mRNA Type
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE mRNA Platform Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Usability
        • 10.3.3.2.3. By mRNA Type
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global mRNA Platform Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Amgen Inc. AstraZeneca PLC
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Asuragen, Inc.
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Catalent Pharma Solutions
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. Arcturus Therapeutics, Inc.
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. BioNTech AG
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. CRISPR Therapeutics Inc.
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. AKESOgen, Inc.
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Baseclick GmbH
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Accent Therapeutics Inc.
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10. Accanis Biotech F&E GmbH & Co KG
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer